Study Stopped
Principal Investigator retired before study completed.
The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer
1 other identifier
interventional
14
1 country
1
Brief Summary
This study will determine the efficacy of cryotherapy to prevent paclitaxel-induced peripheral neuropathy and nail changes in women with breast cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Aug 2020
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 4, 2020
CompletedFirst Submitted
Initial submission to the registry
September 3, 2020
CompletedFirst Posted
Study publicly available on registry
September 22, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 3, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
February 3, 2021
CompletedMarch 8, 2021
March 1, 2021
6 months
September 3, 2020
March 4, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Numbness,tingling,pain ,nail toxicities
absence of numbness and tingling in the treated hands/feet * If there is an absence of pain in the treated hands/feet * If there is an absence of nail changes in the treated hands/feet
13 weeks
Study Arms (2)
Interventioncryotherapy/control
ACTIVE COMPARATORSubjects will have one mitt/one slipper and serve as their own control
standard of care
NO INTERVENTIONSubjects will have two mitts/slippers
Interventions
Eligibility Criteria
You may qualify if:
- Females 18 or older
- Histologically confirmed diagnosis of breast cancer
- Receiving neo-adjuvant or adjuvant dose-dense anthracycline (AC) plus taxane-based chemotherapy or paclitaxel in combination with trastuzumab and pertuzumab
You may not qualify if:
- Prior taxane therapy
- Prior oxaliplatin therapy
- Non-English speaking
- History of peripheral neuropathy, i.e., Buerger's disease
- History of diabetes mellitus
- Pre-existing peripheral neuropathy from other conditions, e.g., Raynaud's disease, Guillain-Barre, Miller Fisher Syndrome
- Hand, nail or foot conditions, e.g., hand/foot syndrome, arthritis, hammer toe, carpal tunnel, bunions, deformities
- Alcohol abuse (history/current)
- Current medication usage of opioids, anti-depressants, anti-convulsants, glutamines, vitamin B12
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Parkview Healthlead
Study Sites (1)
Parkview Cancer Institute
Fort Wayne, Indiana, 46845, United States
Related Publications (69)
Alessandrini A, Starace M, Cere G, Brandi N, Piraccini BM. Management and Outcome of Taxane-Induced Nail Side Effects: Experience of 79 Patients from a Single Centre. Skin Appendage Disord. 2019 Aug;5(5):276-282. doi: 10.1159/000497824. Epub 2019 Mar 22.
PMID: 31559250BACKGROUNDAutissier E. Chemotherapy-Induced Peripheral Neuropathy: Association With Increased Risk of Falls and Injuries. Clin J Oncol Nurs. 2019 Aug 1;23(4):405-410. doi: 10.1188/19.CJON.405-410.
PMID: 31322611BACKGROUNDArgyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res. 2014 Mar 19;6:135-47. doi: 10.2147/CMAR.S44261. eCollection 2014.
PMID: 24672257BACKGROUNDBandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL 3rd, Brufsky AM, Julian TB, Margolese RG, McCarron EC, Ganz PA. Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst. 2018 Feb 1;110(2):djx162. doi: 10.1093/jnci/djx162.
PMID: 28954297BACKGROUNDBouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, Rostaing S, Lanteri-Minet M, Collin E, Grisart J, Boureau F. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004 Apr;108(3):248-257. doi: 10.1016/j.pain.2003.12.024.
PMID: 15030944BACKGROUNDBhatnagar B, Gilmore S, Goloubeva O, Pelser C, Medeiros M, Chumsri S, Tkaczuk K, Edelman M, Bao T. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus. 2014 Jul 16;3:366. doi: 10.1186/2193-1801-3-366. eCollection 2014.
PMID: 25089251BACKGROUNDCan G, Aydiner A, Cavdar I. Taxane-induced nail changes: Predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity. Eur J Oncol Nurs. 2012 Jul;16(3):270-5. doi: 10.1016/j.ejon.2011.06.007. Epub 2011 Jul 23.
PMID: 21784705BACKGROUNDCapriotti K, Capriotti JA, Lessin S, Wu S, Goldfarb S, Belum VR, Lacouture ME. The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis. Br J Dermatol. 2015 Sep;173(3):842-5. doi: 10.1111/bjd.13743. Epub 2015 Jul 29. No abstract available.
PMID: 25704465BACKGROUNDChan YN, Jheng YW, Wang PJ, Chen CY, Lin MW, Wang YJ. Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer. Clin J Oncol Nurs. 2019 Oct 1;23(5):494-501. doi: 10.1188/19.CJON.494-501.
PMID: 31538967BACKGROUNDCassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 2002 Oct;29(5 Suppl 15):11-20. doi: 10.1053/sonc.2002.35524.
PMID: 12422304BACKGROUNDChildress J, Lokich J. Cutaneous hand and foot toxicity associated with cancer chemotherapy. Am J Clin Oncol. 2003 Oct;26(5):435-6. doi: 10.1097/01.coc.0000026486.56886.18. No abstract available.
PMID: 14528066BACKGROUNDCleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994 Mar;23(2):129-38.
PMID: 8080219BACKGROUNDCioroiu C, Weimer LH. Update on Chemotherapy-Induced Peripheral Neuropathy. Curr Neurol Neurosci Rep. 2017 Jun;17(6):47. doi: 10.1007/s11910-017-0757-7.
PMID: 28421360BACKGROUNDCunningham D, Gilchrist NL, Forrest GJ, Soukop M. Onycholysis associated with cytotoxic drugs. Br Med J (Clin Res Ed). 1985 Mar 2;290(6469):675-6. doi: 10.1136/bmj.290.6469.675-a. No abstract available.
PMID: 2578850BACKGROUNDDaut RL, Cleeland CS. The prevalence and severity of pain in cancer. Cancer. 1982 Nov 1;50(9):1913-8. doi: 10.1002/1097-0142(19821101)50:93.0.co;2-r.
PMID: 7116316BACKGROUNDDe Giorgi U, Rosti G, Monti M, Frassineti GL, Marangolo M. Onycholysis secondary to multiple paclitaxel 1-hour infusions: possible role for its vehicle (Cremophor EL). Ann Oncol. 2003 Oct;14(10):1588-9. doi: 10.1093/annonc/mdg419. No abstract available.
PMID: 14504063BACKGROUNDDescoeur J, Pereira V, Pizzoccaro A, Francois A, Ling B, Maffre V, Couette B, Busserolles J, Courteix C, Noel J, Lazdunski M, Eschalier A, Authier N, Bourinet E. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med. 2011 May;3(5):266-78. doi: 10.1002/emmm.201100134. Epub 2011 Mar 24.
PMID: 21438154BACKGROUNDEckhoff L, Knoop AS, Jensen MB, Ejlertsen B, Ewertz M. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat. 2013 Nov;142(1):109-18. doi: 10.1007/s10549-013-2728-2. Epub 2013 Oct 17.
PMID: 24132874BACKGROUNDElasto-Gel(2019).Elasto-Gel.Retrieved on December 1,2019 from https://www.elastogels.com/product/elasto-gel-hot-cold-therapy-mitten/
BACKGROUNDForsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, DeAngelis LM. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol. 1997 Oct;35(1):47-53. doi: 10.1023/a:1005805907311.
PMID: 9266440BACKGROUNDFlory SM, Solimando DA Jr, Webster GF, Dunton CJ, Neufeld JM, Haffey MB. Onycholysis associated with weekly administration of paclitaxel. Ann Pharmacother. 1999 May;33(5):584-6. doi: 10.1345/aph.18307.
PMID: 10369623BACKGROUNDGilbar P, Hain A, Peereboom VM. Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract. 2009 Sep;15(3):143-55. doi: 10.1177/1078155208100450. Epub 2009 Jan 26.
PMID: 19171552BACKGROUNDGriffiths C, Kwon N, Beaumont JL, Paice JA. Cold therapy to prevent paclitaxel-induced peripheral neuropathy. Support Care Cancer. 2018 Oct;26(10):3461-3469. doi: 10.1007/s00520-018-4199-9. Epub 2018 Apr 21.
PMID: 29681015BACKGROUNDGrisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012 Sep;14 Suppl 4(Suppl 4):iv45-54. doi: 10.1093/neuonc/nos203.
PMID: 23095830BACKGROUNDHanai A, Ishiguro H, Sozu T, Tsuda M, Yano I, Nakagawa T, Imai S, Hamabe Y, Toi M, Arai H, Tsuboyama T. Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. J Natl Cancer Inst. 2018 Feb 1;110(2):141-148. doi: 10.1093/jnci/djx178.
PMID: 29924336BACKGROUNDHausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006 Feb;33(1):15-49. doi: 10.1053/j.seminoncol.2005.12.010.
PMID: 16473643BACKGROUNDHershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL; American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014 Jun 20;32(18):1941-67. doi: 10.1200/JCO.2013.54.0914. Epub 2014 Apr 14.
PMID: 24733808BACKGROUNDHoffman,K. (2014). Diagnosing and Treating Chemotherapy-Induced Nail Changes. Podiatry Today,27(2). Retrieved on December 16, 2019from https://www.podiatrytoday.com/diagnosing-and-treating-chemotherapy-induced-nail-changes
BACKGROUNDHussain S, Anderson DN, Salvatti ME, Adamson B, McManus M, Braverman AS. Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer. 2000 May 15;88(10):2367-71. doi: 10.1002/(sici)1097-0142(20000515)88:103.0.co;2-#.
PMID: 10820360BACKGROUNDIshiguro H, Takashima S, Yoshimura K, Yano I, Yamamoto T, Niimi M, Yamashiro H, Ueno T, Takeuchi M, Sugie T, Yanagihara K, Toi M, Fukushima M. Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients. Support Care Cancer. 2012 Sep;20(9):2017-24. doi: 10.1007/s00520-011-1308-4. Epub 2011 Nov 16.
PMID: 22086405BACKGROUNDLaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2013 Jul;37:231-9. doi: 10.1016/j.neuro.2013.05.008. Epub 2013 May 24.
PMID: 23711742BACKGROUNDLee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006 Apr 1;24(10):1633-42. doi: 10.1200/JCO.2005.04.0543.
PMID: 16575015BACKGROUNDKadakia KC, Rozell SA, Butala AA, Loprinzi CL. Supportive cryotherapy: a review from head to toe. J Pain Symptom Manage. 2014 Jun;47(6):1100-15. doi: 10.1016/j.jpainsymman.2013.07.014. Epub 2013 Nov 7.
PMID: 24210702BACKGROUNDKerckhove N, Collin A, Conde S, Chaleteix C, Pezet D, Balayssac D. Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. Front Pharmacol. 2017 Feb 24;8:86. doi: 10.3389/fphar.2017.00086. eCollection 2017.
PMID: 28286483BACKGROUNDKolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, Mooney K. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling. JAMA Neurol. 2016 Jul 1;73(7):860-6. doi: 10.1001/jamaneurol.2016.0383.
PMID: 27183099BACKGROUNDKumar SP. Utilization of brief pain inventory as an assessment tool for pain in patients with cancer: a focused review. Indian J Palliat Care. 2011 May;17(2):108-15. doi: 10.4103/0973-1075.84531.
PMID: 21976850BACKGROUNDLau CP, Hui P, Chan TC. Docetaxel-induced nail toxicity: a case of severe onycholysis and topic review. Chin Med J (Engl). 2011 Aug;124(16):2559-60.
PMID: 21933605BACKGROUNDMcCarthy AL, Shaban RZ, Gillespie K, Vick J. Cryotherapy for docetaxel-induced hand and nail toxicity: randomised control trial. Support Care Cancer. 2014 May;22(5):1375-83. doi: 10.1007/s00520-013-2095-x. Epub 2013 Dec 22.
PMID: 24362908BACKGROUNDMemorial Sloan Kettering Cancer Center (2017) Nail changes during treatment with Taxane-based chemotherapy Retrieved December17,2019 from https://www.mskcc.org/pdf/cancer-care/patient-education/nail-changes-during-treatment-taxanes
BACKGROUNDMiltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev. 2014 Aug;40(7):872-82. doi: 10.1016/j.ctrv.2014.04.004. Epub 2014 Apr 18.
PMID: 24830939BACKGROUNDMinisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C, Puglisi F. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol. 2003 Feb;14(2):333-7. doi: 10.1093/annonc/mdg050.
PMID: 12562663BACKGROUNDMonjazeb S, Wilson J. Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management. Skin Therapy Lett. 2017 Sep;22(5):5-7.
PMID: 28888217BACKGROUNDNicolopoulos J, Howard A. Docetaxel-induced nail dystrophy. Australas J Dermatol. 2002 Nov;43(4):293-6. doi: 10.1046/j.1440-0960.2002.00616.x.
PMID: 12423438BACKGROUNDOncology Nursing Society.(2017). Cutaneous reactions. Retrieved on December 11, 2019 from https://www.ons.org/pep/skin-reactions
BACKGROUNDOncology Nursing Society.(2019). Peripheral neuropathy . Retrieved on December 11, 2019 from https://www.ons.org/pep/peripheral-neuropathy
BACKGROUNDPark SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013 Nov-Dec;63(6):419-37. doi: 10.3322/caac.21204.
PMID: 24590861BACKGROUNDPaul LJ, Cohen PR. Paclitaxel-associated subungual pyogenic granuloma: report in a patient with breast cancer receiving paclitaxel and review of drug-induced pyogenic granulomas adjacent to and beneath the nail. J Drugs Dermatol. 2012 Feb;11(2):262-8.
PMID: 22270214BACKGROUNDPeyton L, Fischer-Cartlidge E. Extremity Cooling: A Synthesis of Cryotherapy Interventions to Reduce Peripheral Neuropathy and Nail Changes From Taxane-Based Chemotherapy. Clin J Oncol Nurs. 2019 Oct 1;23(5):522-528. doi: 10.1188/19.CJON.522-528.
PMID: 31538978BACKGROUNDPoncelet AN. An algorithm for the evaluation of peripheral neuropathy. Am Fam Physician. 1998 Feb 15;57(4):755-64.
PMID: 9490998BACKGROUNDQuasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002 Jan;249(1):9-17. doi: 10.1007/pl00007853.
PMID: 11954874BACKGROUNDRapid Aid. (2020). Cold Gel Slippers. Retrieved on March 2,2020 from http://rapidaid.com/product/hot-cold-gel-slippers/
BACKGROUNDRobert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, Baran R. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015 Apr;16(4):e181-9. doi: 10.1016/S1470-2045(14)71133-7.
PMID: 25846098BACKGROUNDRoss M, Fischer-Cartlidge E. Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia . Clin J Oncol Nurs. 2017 Apr 1;21(2):226-233. doi: 10.1188/17.CJON.226-233.
PMID: 28315539BACKGROUNDSanofi (2019).Taxotere prescribing information. Retreived on December 11, 2019 from http://products.sanofi.us/taxotere/Taxotere.html
BACKGROUNDSato J, Mori M, Nihei S, Kumagai M, Takeuchi S, Kashiwaba M, Kudo K. The effectiveness of regional cooling for paclitaxel-induced peripheral neuropathy. J Pharm Health Care Sci. 2016 Nov 15;2:33. doi: 10.1186/s40780-016-0067-2. eCollection 2016.
PMID: 27891244BACKGROUNDScotte F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, Magherini E, Fabre-Guillevin E, Andrieu JM, Oudard S. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol. 2005 Jul 1;23(19):4424-9. doi: 10.1200/JCO.2005.15.651.
PMID: 15994152BACKGROUNDScotte F, Banu E, Medioni J, Levy E, Ebenezer C, Marsan S, Banu A, Tourani JM, Andrieu JM, Oudard S. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer. 2008 Apr 1;112(7):1625-31. doi: 10.1002/cncr.23333.
PMID: 18286527BACKGROUNDSeretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014 Dec;155(12):2461-2470. doi: 10.1016/j.pain.2014.09.020. Epub 2014 Sep 23.
PMID: 25261162BACKGROUNDSpazzapan S, Crivellari D, Lombardi D, Scuderi C, Magri MD, Veronesi A, Gatti A. Nail toxicity related to weekly taxanes: an important issue requiring a change in common toxicity criteria grading? J Clin Oncol. 2002 Nov 1;20(21):4404-5; author reply 4405. doi: 10.1200/JCO.2002.99.147. No abstract available.
PMID: 12409345BACKGROUNDStarobova H, Vetter I. Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Front Mol Neurosci. 2017 May 31;10:174. doi: 10.3389/fnmol.2017.00174. eCollection 2017.
PMID: 28620280BACKGROUNDSundar R, Bandla A, Tan SS, Liao LD, Kumarakulasinghe NB, Jeyasekharan AD, Ow SG, Ho J, Tan DS, Lim JS, Vijayan J, Therimadasamy AK, Hairom Z, Ang E, Ang S, Thakor NV, Lee SC, Wilder-Smith EP. Limb Hypothermia for Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Study. Front Oncol. 2017 Jan 10;6:274. doi: 10.3389/fonc.2016.00274. eCollection 2016.
PMID: 28119855BACKGROUNDSwenson KK, Bell EM, Nissen J. Nail toxicity associated with paclitaxel treatment for ovarian cancer. Oncol Nurs Forum. 2013 Jan;40(1):17-9. doi: 10.1188/13.ONF.17-19. No abstract available.
PMID: 23269765BACKGROUNDTofthagen C, Visovsky CM, Hopgood R. Chemotherapy-induced peripheral neuropathy: an algorithm to guide nursing management. Clin J Oncol Nurs. 2013 Apr;17(2):138-44. doi: 10.1188/13.CJON.138-144.
PMID: 23538249BACKGROUNDU.S Department of Health and Human Services (2017). Common Terminology Criteria for Adverse Events (CTCAE v. 5.0) Retrieved on December 12, 2019 from https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.
BACKGROUNDWickham R. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. Clin J Oncol Nurs. 2007 Jun;11(3):361-76. doi: 10.1188/07.CJON.361-376.
PMID: 17623621BACKGROUNDWildes TM, Dua P, Fowler SA, Miller JP, Carpenter CR, Avidan MS, Stark S. Systematic review of falls in older adults with cancer. J Geriatr Oncol. 2015 Jan;6(1):70-83. doi: 10.1016/j.jgo.2014.10.003. Epub 2014 Oct 30.
PMID: 25454770BACKGROUNDWilkinson,M., Cocilovo,C., & Schar,M. (2016) Reduction of paclitaxel neuropathy with cryotherapy.Journal of Clinical Oncology.34(suppl 3S;abst 124) retrieved on December 2,2019 from https://meetinglibrary.asco.org/record/119151/abstract
BACKGROUNDWillis, W.D (2000). The nervous system. In R.M. Berne & M.N. Levy (Eds.). Principles of physiology (pp. 68-94). St. Louis: Mosby.
BACKGROUNDWinters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, Stoyles S, Faithfull S. Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy. J Clin Oncol. 2017 Aug 10;35(23):2604-2612. doi: 10.1200/JCO.2016.71.3552. Epub 2017 Jun 6.
PMID: 28586243BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Danielle R Payne, MSN
Parkview Health
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prinicipal Investigator
Study Record Dates
First Submitted
September 3, 2020
First Posted
September 22, 2020
Study Start
August 4, 2020
Primary Completion
February 3, 2021
Study Completion
February 3, 2021
Last Updated
March 8, 2021
Record last verified: 2021-03
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- Immediately following publication and no end date
- Access Criteria
- Data will be available to anyone who wishes to access the data for any purpose by contacting nancy.ehmke@parkview.com
The following will be shared: Individual participant data that underlie the results reported in the planned article after deidentification including text,tables,figures, appendices